← Leaderboards
Grace Dy
State University Of New York At Buffalo
$1,167,635
Attributed
$3,502,906
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,502,906 · 2
By mechanism
R01$3,075,394 · 1
R21$427,512 · 1
Top collaborators
- Yun Wu6 shared
- Fumito Ito4 shared
- Kate W Rittenhouse-Olson2 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Yun Wu$3,163,825
- Qiaoqiang Gan$282,714
- Janet R Morrow$992,079
Others in their field
Other Rising Stars on “Low Dose Computed Tomography”
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Matthew Adam Triplette · Fred Hutchinson Cancer Center$2,246,937
- Jinsong Huang · Univ Of North Carolina Chapel Hill$1,348,782
- Akl C Fahed · Massachusetts General Hospital$1,242,113
- Philip T Veliz · University Of Michigan At Ann Arbor$1,031,095
- Jennifer Ann Richmond · Vanderbilt University Medical Center$1,018,408
Research focus
Low Dose Computed TomographyMedical ImagingDiagnostic ValueLiquid BiopsyLung Cancer ScreeningMalignant NeoplasmsDiagnosticDiagnostic AccuracyExosomeHigh RiskCost EffectiveBiopsyArea Under CurveMalignant Neoplasm Of LungBloodComplementCancer BiomarkersCellsCohortEarly DiagnosisBiological MarkersCancer PatientConsumptionMicrornas
Grant awards (6)
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$1,236,637
R01 · FY2025 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$615,852
R01 · FY2024 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$630,231
R01 · FY2023 · CA
Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection$219,559
R21 · FY2023 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$592,674
R01 · FY2022 · CA
Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection$207,953
R21 · FY2022 · CA